{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:54:56Z","timestamp":1790510096658,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research, Royal Cancer Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009756","name":"Sarcoma UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"name":"As above"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular endothelial growth factor receptors, preclinical work indicates that pazopanib exerts an anticancer effect through the inhibition of both angiogenic and oncogenic signaling pathways. Following the establishment of optimal dosing and safety profiles in early phase studies and approval for the treatment of advanced renal cell carcinoma, pazopanib was investigated in STS. A landmark phase III randomized study demonstrated improved progression-free survival with pazopanib compared to that with placebo in pretreated patients with STS of various subtypes. The efficacy of pazopanib in specific STS subtypes has been further described in real-world-based case series in both mixed and subtype-specific STS cohorts. At present, there are no clinically validated predictive biomarkers for use in selecting patients with advanced STS for pazopanib therapy, limiting the clinical effectiveness and cost-effectiveness of the drug. In this review, we summarize the preclinical and clinical data for pazopanib, outline the evidence base for its effect in STS and explore reported studies that have investigated putative biomarkers.<\/jats:p>","DOI":"10.1038\/s41392-019-0049-6","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T23:05:23Z","timestamp":1558047923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Pazopanib in advanced soft tissue sarcomas"],"prefix":"10.1038","volume":"4","author":[{"given":"Alex T. J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"49_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/gtc.12022","volume":"18","author":"D Kitagawa","year":"2013","unstructured":"Kitagawa, D. et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 18, 110\u2013122 (2013).","journal-title":"Genes Cells"},{"key":"49_CR2","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1021\/pr401247t","volume":"13","author":"X Ku","year":"2014","unstructured":"Ku, X., Heinzlmeir, S., Helm, D., M\u00e9dard, G. & Kuster, B. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics. J. Proteome Res. 13, 2445\u20132452 (2014).","journal-title":"J. Proteome Res."},{"key":"49_CR3","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","volume":"6","author":"R Kumar","year":"2007","unstructured":"Kumar, R. et al. Pharmacokinetic\u2013pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6, 2012\u20132021 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"49_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/annonc\/mdw030","volume":"27","author":"J Noujaim","year":"2016","unstructured":"Noujaim, J., Payne, L. S., Judson, I., Jones, R. L. & Huang, P. H. Phosphoproteomics in translational research: a sarcoma perspective. Ann. Oncol. 27, 787\u2013794 (2016).","journal-title":"Ann. Oncol."},{"key":"49_CR5","doi-asserted-by":"publisher","first-page":"19478","DOI":"10.1073\/pnas.0609329103","volume":"103","author":"K Podar","year":"2006","unstructured":"Podar, K. et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA 103, 19478\u201319483 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"49_CR6","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf, W. T. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879\u20131886 (2012).","journal-title":"Lancet"},{"key":"49_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3747\/co.21.1899","volume":"21","author":"TE Delea","year":"2014","unstructured":"Delea, T. E. et al. Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada. Curr. Oncol. 21, 748 (2014).","journal-title":"Curr. Oncol."},{"key":"49_CR8","doi-asserted-by":"publisher","first-page":"481071","DOI":"10.1155\/2014\/481071","volume":"2014","author":"J Amdahl","year":"2014","unstructured":"Amdahl, J. et al. Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom. Sarcoma 2014, 481071 (2014).","journal-title":"Sarcoma"},{"key":"49_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12094-014-1191-9","volume":"17","author":"G Villa","year":"2014","unstructured":"Villa, G., Hern\u00e1ndez-Pastor, L. J., Guix, M., Lavernia, J. & Cuesta, M. Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain. Clin. Transl. Oncol. 17, 24\u201333 (2014).","journal-title":"Clin. Transl. Oncol."},{"key":"49_CR10","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1021\/jm800566m","volume":"51","author":"PA Harris","year":"2008","unstructured":"Harris, P. A. et al. Discovery of 5-[[4-[(2,3-Dimethyl-2 H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor \u2020. J. Med. Chem. 51, 4632\u20134640 (2008).","journal-title":"J. Med. Chem."},{"key":"49_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/1078-0432.CCR-10-1603","volume":"17","author":"B Gril","year":"2011","unstructured":"Gril, B. et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin. Cancer Res. 17, 142\u2013153 (2011).","journal-title":"Clin. Cancer Res."},{"key":"49_CR12","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.ajpath.2013.02.043","volume":"182","author":"B Gril","year":"2013","unstructured":"Gril, B. et al. Pazopanib inhibits the activation of PDGFR\u03b2-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am. J. Pathol. 182, 2368\u20132379 (2013).","journal-title":"Am. J. Pathol."},{"key":"49_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025625","volume":"6","author":"B Gril","year":"2011","unstructured":"Gril, B. et al. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS ONE 6, e25625 (2011).","journal-title":"PLoS ONE"},{"key":"49_CR14","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz, H. I. et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15, 4220\u20134227 (2009).","journal-title":"Clin. Cancer Res."},{"key":"49_CR15","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","volume":"31","author":"JL Glade Bender","year":"2013","unstructured":"Glade Bender, J. L. et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a Children\u2019s Oncology Group Phase I Consortium Report. J. Clin. Oncol. 31, 3034\u20133043 (2013).","journal-title":"J. Clin. Oncol."},{"key":"49_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a Randomized Phase III trial. J. Clin. Oncol. 28, 1061\u20131068 (2010).","journal-title":"J. Clin. Oncol."},{"key":"49_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722\u2013731 (2013).","journal-title":"N. Engl. J. Med."},{"key":"49_CR18","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer, S. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620). J. Clin. Oncol. 27, 3126\u20133132 (2009).","journal-title":"J. Clin. Oncol."},{"key":"49_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","volume":"38","author":"M Van Glabbeke","year":"2002","unstructured":"Van Glabbeke, M., Verweij, J., Judson, I. & Nielsen, O. S. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38, 543\u2013549 (2002).","journal-title":"Eur. J. Cancer"},{"key":"49_CR20","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1002\/cncr.29426","volume":"121","author":"C Coens","year":"2015","unstructured":"Coens, C. et al. Health-related quality-of-life results from PALETTE: a randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for res. Cancer 121, 2933\u20132941 (2015).","journal-title":"Cancer"},{"key":"49_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/jjco\/hyv184","volume":"46","author":"A Kawai","year":"2016","unstructured":"Kawai, A. et al. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn. J. Clin. Oncol. 46, 248\u2013253 (2016).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"49_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-018-0617-1","volume":"11","author":"J Guo","year":"2018","unstructured":"Guo, J. et al. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. J. Hematol. Oncol. 11, 69 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"49_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-014-2374-3","volume":"73","author":"M Inada-Inoue","year":"2014","unstructured":"Inada-Inoue, M. et al. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother. Pharmacol. 73, 673\u2013683 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"49_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/0165-6147(91)90516-U","volume":"12","author":"W Kalow","year":"1991","unstructured":"Kalow, W. Interethnic variation of drug metabolism. Trends Pharmacol. Sci. 12, 102\u2013107 (1991).","journal-title":"Trends Pharmacol. Sci."},{"key":"49_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/17425250902800153","volume":"5","author":"VH Phan","year":"2009","unstructured":"Phan, V. H. et al. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin. Drug Metab. Toxicol. 5, 243\u2013257 (2009).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"49_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ygyno.2016.03.024","volume":"142","author":"C Benson","year":"2016","unstructured":"Benson, C. et al. Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Gynecol. Oncol. 142, 89\u201394 (2016).","journal-title":"Gynecol. Oncol."},{"key":"49_CR27","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1080\/0284186X.2017.1332779","volume":"56","author":"H Gelderblom","year":"2017","unstructured":"Gelderblom, H. et al. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study*. Acta Oncol. 56, 1769\u20131775 (2017).","journal-title":"Acta Oncol."},{"key":"49_CR28","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1002\/cncr.30926","volume":"123","author":"BL Samuels","year":"2017","unstructured":"Samuels, B. L. et al. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 123, 4640\u20134647 (2017).","journal-title":"Cancer"},{"key":"49_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/JCO.2017.74.9598","volume":"36","author":"ATJ Lee","year":"2018","unstructured":"Lee, A. T. J., Thway, K., Huang, P. H. & Jones, R. L. Clinical and molecular spectrum of liposarcoma. J. Clin. Oncol. 36, 151\u2013159 (2018).","journal-title":"J. Clin. Oncol."},{"key":"49_CR30","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-17-0272","volume":"23","author":"V Subbiah","year":"2017","unstructured":"Subbiah, V. et al. Phase Ib\/II study of the safety and efficacy of combination therapy with multikinase VEGF inhibitor pazopanib and MEK inhibitor trametinib in advanced soft tissue sarcoma. Clin. Cancer Res. 23, 4027\u20134034 (2017).","journal-title":"Clin. Cancer Res."},{"key":"49_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13114-8","volume":"7","author":"V Dembla","year":"2017","unstructured":"Dembla, V. et al. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci. Rep. 7, 15963 (2017).","journal-title":"Sci. Rep."},{"key":"49_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1634\/theoncologist.2015-0245","volume":"20","author":"RR Munhoz","year":"2015","unstructured":"Munhoz, R. R. et al. A Phase Ib\/II study of gemcitabine and docetaxel in combination with pazopanib for the neoadjuvant treatment of soft tissue sarcomas. Oncologist 20, 1245\u20131246 (2015).","journal-title":"Oncologist"},{"key":"49_CR33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/annonc\/mdv066","volume":"26","author":"S Fu","year":"2015","unstructured":"Fu, S. et al. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann. Oncol. 26, 1012\u20131018 (2015).","journal-title":"Ann. Oncol."},{"key":"49_CR34","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso, M. R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610\u20132621 (2006).","journal-title":"J. Clin. Invest."},{"key":"49_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M P\u00e0ez-Ribes","year":"2009","unstructured":"P\u00e0ez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220\u2013231 (2009).","journal-title":"Cancer Cell"},{"key":"49_CR36","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","volume":"18","author":"AW Griffioen","year":"2012","unstructured":"Griffioen, A. W. et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin. Cancer Res. 18, 3961\u20133971 (2012).","journal-title":"Clin. Cancer Res."},{"key":"49_CR37","first-page":"10009","volume":"30","author":"WTA Van Der Graaf","year":"2012","unstructured":"Van Der Graaf, W. T. A. et al. PALETTE: final overall survival (OS) data and predictive factors for OS of EORTC 62072\/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients. ASCO Meet. Abstr. 30, 10009 (2012).","journal-title":"ASCO Meet. Abstr."},{"key":"49_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdt586","volume":"25","author":"B Kasper","year":"2014","unstructured":"Kasper, B. et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann. Oncol. 25, 719\u2013724 (2014).","journal-title":"Ann. Oncol."},{"key":"49_CR39","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi, H. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753\u20131759 (2007).","journal-title":"J. Clin. Oncol."},{"key":"49_CR40","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1200\/JCO.2006.07.3411","volume":"25","author":"RS Benjamin","year":"2007","unstructured":"Benjamin, R. S. et al. We should desist using RECIST, at least in GIST. J. Clin. Oncol. 25, 1760\u20131764 (2007).","journal-title":"J. Clin. Oncol."},{"key":"49_CR41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1148\/radiol.2512081403","volume":"251","author":"S Stacchiotti","year":"2009","unstructured":"Stacchiotti, S. et al. High-grade soft-tissue sarcomas: tumor response assessment\u2014pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251, 447\u2013456 (2009).","journal-title":"Radiology"},{"key":"49_CR42","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1002\/cncr.27624","volume":"118","author":"S Stacchiotti","year":"2012","unstructured":"Stacchiotti, S. et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 118, 5857\u20135866 (2012).","journal-title":"Cancer"},{"key":"49_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-015-0022-2","volume":"5","author":"M Maruzzo","year":"2015","unstructured":"Maruzzo, M. et al. Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience. Clin. Sarcoma Res. 5, 5 (2015).","journal-title":"Clin. Sarcoma Res."},{"key":"49_CR44","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1016\/j.ejca.2014.09.004","volume":"50","author":"S Stacchiotti","year":"2014","unstructured":"Stacchiotti, S. et al. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. Eur. J. Cancer 50, 3021\u20133028 (2014).","journal-title":"Eur. J. Cancer"},{"key":"49_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","volume":"20","author":"J Martin-Broto","year":"2019","unstructured":"Martin-Broto, J. et al. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 20, 134\u2013144 (2019).","journal-title":"Lancet Oncol."},{"key":"49_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009558","volume":"6","author":"U Ronellenfitsch","year":"2016","unstructured":"Ronellenfitsch, U. et al. Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04\/NOPASS). BMJ Open 6, e009558 (2016).","journal-title":"BMJ Open"},{"key":"49_CR47","doi-asserted-by":"crossref","unstructured":"Narahara, H. et al. 508P Prognostic factors of soft tissue sarcoma (STS) treated with pazopanib from Nishinomiya Sarcoma Cohort Study (NSCS). Ann. Oncol. 27, (supp 9) (2016).","DOI":"10.1093\/annonc\/mdw597.008"},{"key":"49_CR48","doi-asserted-by":"publisher","first-page":"11555","DOI":"10.1200\/JCO.2018.36.15_suppl.11555","volume":"36","author":"WTA Van Der Graaf","year":"2018","unstructured":"Van Der Graaf, W. T. A. et al. Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study). J. Clin. Oncol. 36, 11555\u201311555 (2018).","journal-title":"J. Clin. Oncol."},{"key":"49_CR49","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle, A. B. et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br. J. Cancer 111, 1909\u20131916 (2014).","journal-title":"Br. J. Cancer"},{"key":"49_CR50","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(16)00075-9","volume":"17","author":"O Mir","year":"2016","unstructured":"Mir, O. et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol. 17, 632\u2013641 (2016).","journal-title":"Lancet Oncol."},{"key":"49_CR51","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/bcp.13327","volume":"83","author":"NAG Lankheet","year":"2017","unstructured":"Lankheet, N. A. G. et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br. J. Clin. Pharmacol. 83, 2195\u20132204 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"49_CR52","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1016\/j.ejca.2015.08.002","volume":"51","author":"F Duffaud","year":"2015","unstructured":"Duffaud, F. et al. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. Eur. J. Cancer 51, 2615\u20132623 (2015).","journal-title":"Eur. J. Cancer"},{"key":"49_CR53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejca.2015.10.006","volume":"53","author":"D Goldstein","year":"2016","unstructured":"Goldstein, D. et al. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced\/metastatic renal cell carcinoma? Eur. J. Cancer 53, 96\u2013104 (2016).","journal-title":"Eur. J. Cancer"},{"key":"49_CR54","doi-asserted-by":"publisher","unstructured":"Vos, M. et al. Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. Acta Oncol. 1\u20138 (2019). https:\/\/doi.org\/10.1080\/0284186X.2019.1581376.","DOI":"10.1080\/0284186X.2019.1581376"},{"key":"49_CR55","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00280-017-3463-x","volume":"80","author":"RB Verheijen","year":"2017","unstructured":"Verheijen, R. B. et al. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemother. Pharmacol. 80, 1171\u20131178 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"49_CR56","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","volume":"25","author":"O Mir","year":"2019","unstructured":"Mir, O. et al. Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 trials. Clin. Cancer Res. 25, 1479\u20131485 (2019).","journal-title":"Clin. Cancer Res."},{"key":"49_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000013","volume":"1","author":"A Rodriguez-Vida","year":"2016","unstructured":"Rodriguez-Vida, A., Strijbos, M. & Hutson, T. Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma: Table 1. ESMO Open 1, e000013 (2016).","journal-title":"ESMO Open"},{"key":"49_CR58","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","volume":"13","author":"HT Tran","year":"2012","unstructured":"Tran, H. T. et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 13, 827\u2013837 (2012).","journal-title":"Lancet Oncol."},{"key":"49_CR59","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1016\/j.clgc.2017.10.017","volume":"16","author":"A Verbiest","year":"2018","unstructured":"Verbiest, A. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with outcome during pazopanib therapy in the metastatic setting. Clin. Genitourin. Cancer 16, e605\u2013e612 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"49_CR60","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-13-0491","volume":"19","author":"TK Choueiri","year":"2013","unstructured":"Choueiri, T. K. et al. The role of aberrant VHL\/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin. Cancer Res. 19, 5218\u20135226 (2013).","journal-title":"Clin. Cancer Res."},{"key":"49_CR61","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/bjc.2012.328","volume":"107","author":"S Sleijfer","year":"2012","unstructured":"Sleijfer, S. et al. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br. J. Cancer 107, 639\u2013645 (2012).","journal-title":"Br. J. Cancer"},{"key":"49_CR62","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl Cancer Inst. 106, dju124 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"49_CR63","doi-asserted-by":"crossref","unstructured":"De Maio, E. et al. Evolution in neutrophil-to-lymphocyte ratio (NLR) among advanced soft tissue sarcoma (STS) patients treated with pazopanib within EORTC 62043\/62072 trials. Ann. Oncol. 28, (supp 5) (2017).","DOI":"10.1093\/annonc\/mdx387.028"},{"key":"49_CR64","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s10147-017-1199-6","volume":"23","author":"H Kobayashi","year":"2018","unstructured":"Kobayashi, H. et al. Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma. Int. J. Clin. Oncol. 23, 368\u2013374 (2018).","journal-title":"Int. J. Clin. Oncol."},{"key":"49_CR65","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1093\/annonc\/mdv497","volume":"26","author":"K Koehler","year":"2015","unstructured":"Koehler, K., Liebner, D. & Chen, J. L. TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann. Oncol. 26, 2361\u20132362 (2015).","journal-title":"Ann. Oncol."},{"key":"49_CR66","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.celrep.2016.10.005","volume":"17","author":"JP Wong","year":"2016","unstructured":"Wong, J. P. et al. Dual targeting of PDGFR\u03b1 and FGFR1 displays synergistic efficacy in malignant rhabdoid tumors. Cell Rep. 17, 1265\u20131275 (2016).","journal-title":"Cell Rep."},{"key":"49_CR67","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jprot.2017.08.015","volume":"170","author":"S Vyse","year":"2018","unstructured":"Vyse, S. et al. Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. J. Proteomics 170, 130\u2013140 (2018).","journal-title":"J. Proteomics"},{"key":"49_CR68","doi-asserted-by":"crossref","first-page":"109587","DOI":"10.18632\/oncotarget.22730","volume":"8","author":"Z Qiao","year":"2017","unstructured":"Qiao, Z. et al. Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma. Oncotarget 8, 109587\u2013109595 (2017).","journal-title":"Oncotarget"},{"key":"49_CR69","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nm.2174","volume":"16","author":"F Chibon","year":"2010","unstructured":"Chibon, F. et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat. Med. 16, 781\u2013787 (2010).","journal-title":"Nat. Med."},{"key":"49_CR70","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1158\/1078-0432.CCR-14-3141","volume":"21","author":"X Guo","year":"2015","unstructured":"Guo, X. et al. Clinically relevant molecular subtypes in leiomyosarcoma. Clin. Cancer Res. 21, 3501\u20133511 (2015).","journal-title":"Clin. Cancer Res."},{"key":"49_CR71","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"A Abeshouse","year":"2017","unstructured":"Abeshouse, A. et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950\u2013965.e28 (2017).","journal-title":"Cell"},{"key":"49_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-4-7","volume":"4","author":"A Frezza","year":"2014","unstructured":"Frezza, A. et al. Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. Clin. Sarcoma Res. 4, 7 (2014).","journal-title":"Clin. Sarcoma Res."},{"key":"49_CR73","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","volume":"23","author":"S Stacchiotti","year":"2018","unstructured":"Stacchiotti, S. et al. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist 23, 62\u201370 (2018).","journal-title":"Oncologist"},{"key":"49_CR74","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0219","volume":"4","author":"AM Frezza","year":"2018","unstructured":"Frezza, A. M. et al. Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma. JAMA Oncol. 4, e180219 (2018).","journal-title":"JAMA Oncol."},{"key":"49_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-1030-2","volume":"34","author":"RL Jones","year":"2017","unstructured":"Jones, R. L. et al. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Med. Oncol. 34, 167 (2017).","journal-title":"Med. Oncol."},{"key":"49_CR76","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","volume":"56","author":"A Koll\u00e1r","year":"2017","unstructured":"Koll\u00e1r, A. et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 56, 88\u201392 (2017).","journal-title":"Acta Oncol."},{"key":"49_CR77","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1634\/theoncologist.2017-0408","volume":"23","author":"BA Menegaz","year":"2018","unstructured":"Menegaz, B. A. et al. Clinical activity of pazopanib in patients with advanced desmoplastic small round cell tumor. Oncologist 23, 360\u2013366 (2018).","journal-title":"Oncologist"},{"key":"49_CR78","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/cncr.29961","volume":"122","author":"T Nakamura","year":"2016","unstructured":"Nakamura, T. et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 122, 1408\u20131416 (2016).","journal-title":"Cancer"},{"key":"49_CR79","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/jjco\/hyv022","volume":"45","author":"K Nakano","year":"2015","unstructured":"Nakano, K. et al. Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study. Jpn. J. Clin. Oncol. 45, 449\u2013455 (2015).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"49_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1160-x","volume":"15","author":"KH Yoo","year":"2015","unstructured":"Yoo, K. H. et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer 15, 154 (2015).","journal-title":"BMC Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-019-0049-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-019-0049-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-019-0049-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T14:54:55Z","timestamp":1671202495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-019-0049-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1038\/s41392-019-0049-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"9 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.T.J.L., P.H.H., and R.L.J. are coinventors on a patent application regarding materials and methods for stratifying and treating cancers. R.L.J. has received compensation from Eisai, PharmaMar, Merck, ZIOPHARM and Morphotek for service as a consultant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}